Next Article in Journal
Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol
Next Article in Special Issue
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
Previous Article in Journal
Social Jetlag and Prostate Cancer Incidence in Alberta’s Tomorrow Project: A Prospective Cohort Study
Previous Article in Special Issue
Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
Article

Clinical Significance of Annexin A2 Expression in Breast Cancer Patients

1
Department of Microbiology, Immunology and Genetics, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
2
Department of Pathology, Brookwood Baptist Health, 1130 22nd St S # 1000, Birmingham, AL 35205, USA
3
Department of Biostatistics and Epidemiology, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
4
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
5
Center for Diversity and International Programs, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(1), 2; https://doi.org/10.3390/cancers13010002
Received: 17 November 2020 / Revised: 11 December 2020 / Accepted: 17 December 2020 / Published: 22 December 2020
Annexin A2 (AnxA2) is a Ca++-dependent phospholipid-binding protein that is involved in invasion and metastasis of breast cancer. However, the expression of AnxA2 in breast cancer patients has not been reported. Here, we show that the expression of AnxA2 was high in tumor tissues and serum samples of breast cancer patients compared to non-cancer patients. The high expression of serum AnxA2 in breast cancer was associated with tumor grade and poor survival. The expression and diagnostic value of serum AnxA2 was high in triple-negative breast cancer (TNBC) subtypes and associated with the phosphorylation of AnxA2 at tyrosine 23. Overall, this study highlights the diagnostic and prognostic significance of AnxA2 in breast cancer.
Increasing evidence suggests that AnxA2 contributes to invasion and metastasis of breast cancer. However, the clinical significance of AnxA2 expression in breast cancer has not been reported. The expression of AnxA2 in cell lines, tumor tissues, and serum samples of breast cancer patients were analyzed by immunoblotting, immunohistochemistry, and enzyme-linked immunosorbent assay, respectively. We found that AnxA2 was significantly upregulated in tumor tissues and serum samples of breast cancer patients compared with normal controls. The high expression of serum AnxA2 was significantly associated with tumor grades and poor survival of the breast cancer patients. Based on molecular subtypes, AnxA2 expression was significantly elevated in tumor tissues and serum samples of triple-negative breast cancer (TNBC) patients compared with other breast cancer subtypes. Our analyses on breast cancer cell lines demonstrated that secretion of AnxA2 is associated with its tyrosine 23 (Tyr23) phosphorylation in cells. The expression of non-phosphomimetic mutant of AnxA2 in HCC1395 cells inhibits its secretion from cells compared to wild-type AnxA2, which further suggest that Tyr23 phosphorylation is a critical step for AnxA2 secretion from TNBC cells. Our analysis of AnxA2 phosphorylation in clinical samples further confirmed that the phosphorylation of AnxA2 at Tyr23 was high in tumor tissues of TNBC patients compared to matched adjacent non-tumorigenic breast tissues. Furthermore, we observed that the diagnostic value of serum AnxA2 was significantly high in TNBC compared with other breast cancer subtypes. These findings suggest that serum AnxA2 concentration could be a potential diagnostic biomarker for TNBC patients. View Full-Text
Keywords: breast cancer; annexin A2; biomarker; TNBC breast cancer; annexin A2; biomarker; TNBC
Show Figures

Figure 1

MDPI and ACS Style

Gibbs, L.D.; Mansheim, K.; Maji, S.; Nandy, R.; Lewis, C.M.; Vishwanatha, J.K.; Chaudhary, P. Clinical Significance of Annexin A2 Expression in Breast Cancer Patients. Cancers 2021, 13, 2. https://doi.org/10.3390/cancers13010002

AMA Style

Gibbs LD, Mansheim K, Maji S, Nandy R, Lewis CM, Vishwanatha JK, Chaudhary P. Clinical Significance of Annexin A2 Expression in Breast Cancer Patients. Cancers. 2021; 13(1):2. https://doi.org/10.3390/cancers13010002

Chicago/Turabian Style

Gibbs, Lee D., Kelsey Mansheim, Sayantan Maji, Rajesh Nandy, Cheryl M. Lewis, Jamboor K. Vishwanatha, and Pankaj Chaudhary. 2021. "Clinical Significance of Annexin A2 Expression in Breast Cancer Patients" Cancers 13, no. 1: 2. https://doi.org/10.3390/cancers13010002

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop